Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erwin G Van Meir

Showing results (1-10 of 139) with videos related to

Pageof 14
Sort By:
Nature|June 25, 2004
Opening the chamber of peer-review secretsErwin G Van Meir
Oncoscience|September 14, 2020
The advent of precision epigenetics for medulloblastomaChaoxi Li, Erwin G Van Meir
Scientific Reports|March 16, 2019
A simple genotyping method to detect small CRISPR-Cas9 induced indels by agarose gel electrophoresisDebanjan Bhattacharya, Erwin G Van Meir
Journal of Molecular Medicine (Berlin, Germany)|December 17, 2010
At the crossroads of cancer and inflammation: Ras rewires an HIF-driven IL-1 autocrine loopStefan Kaluz, Erwin G Van Meir
Nature Nanotechnology|June 27, 2017
Cancer therapy: Neutrophils traffic in cancer nanodrugsSatoru Osuka, Erwin G Van Meir
Oncotarget|March 24, 2016
BAI1: from cancer to neurological diseaseDan Zhu, Erwin G Van Meir
The Journal of Clinical Investigation|February 2, 2017
Overcoming therapeutic resistance in glioblastoma: the way forwardSatoru Osuka, Erwin G Van Meir
Oncotarget|March 8, 2011
A conspiracy of glioma and endothelial cells to invade the normal brainAbdessamad Zerrouqi, Erwin G Van Meir
Current Opinion in Investigational Drugs (London, England : 2000)|January 11, 2007
Inhibitors of hypoxia-inducible factor-1 signalingVladimir E Belozerov, Erwin G Van Meir
Anti-Cancer Drugs|September 16, 2005
Hypoxia inducible factor-1: a novel target for cancer therapyVladimir E Belozerov, Erwin G Van Meir
Pageof 14

Showing results (1-10 of 139) with videos related to

Sort By:
Pageof 14
Nature|June 25, 2004
Opening the chamber of peer-review secretsErwin G Van Meir
Oncoscience|September 14, 2020
The advent of precision epigenetics for medulloblastomaChaoxi Li, Erwin G Van Meir
Scientific Reports|March 16, 2019
A simple genotyping method to detect small CRISPR-Cas9 induced indels by agarose gel electrophoresisDebanjan Bhattacharya, Erwin G Van Meir
Journal of Molecular Medicine (Berlin, Germany)|December 17, 2010
At the crossroads of cancer and inflammation: Ras rewires an HIF-driven IL-1 autocrine loopStefan Kaluz, Erwin G Van Meir
Nature Nanotechnology|June 27, 2017
Cancer therapy: Neutrophils traffic in cancer nanodrugsSatoru Osuka, Erwin G Van Meir
Oncotarget|March 24, 2016
BAI1: from cancer to neurological diseaseDan Zhu, Erwin G Van Meir
The Journal of Clinical Investigation|February 2, 2017
Overcoming therapeutic resistance in glioblastoma: the way forwardSatoru Osuka, Erwin G Van Meir
Oncotarget|March 8, 2011
A conspiracy of glioma and endothelial cells to invade the normal brainAbdessamad Zerrouqi, Erwin G Van Meir
Current Opinion in Investigational Drugs (London, England : 2000)|January 11, 2007
Inhibitors of hypoxia-inducible factor-1 signalingVladimir E Belozerov, Erwin G Van Meir
Anti-Cancer Drugs|September 16, 2005
Hypoxia inducible factor-1: a novel target for cancer therapyVladimir E Belozerov, Erwin G Van Meir
Pageof 14